Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Core Viewpoint - Unicycive Therapeutics is under investigation for possible securities fraud following a significant stock price decline after the FDA issued a Complete Response Letter for its New Drug Application [1][3][4] Company Summary - Unicycive Therapeutics, Inc. (NASDAQ: UNCY) has faced legal scrutiny as the Portnoy Law Firm has initiated an investigation into potential securities fraud and may file a class action on behalf of investors [1] - The company received a Complete Response Letter from the FDA regarding its New Drug Application for OLC, which is intended to treat hyperphosphatemia in patients with chronic kidney disease on dialysis [3] - The FDA's response was triggered by deficiencies found in a third-party manufacturing vendor during a cGMP inspection [3] Stock Performance - Following the FDA announcement, Unicycive's stock price fell by $2.03 per share, representing a decline of approximately 29.85%, closing at $4.77 per share on June 30, 2025 [4]